Core Insights - Fifty1 AI Labs, LLC has announced a strategic partnership with the intent to acquire BioSpark AI Technologies Inc., aiming to revolutionize drug repurposing through advanced AI technologies [1][4] - The collaboration will integrate BioSpark's AI and large language model (LLM) platform with Fifty1 AI Labs' predictive modeling to enhance the analysis of extensive medical literature [2][3] Group 1: Partnership and Acquisition - The partnership is designed to leverage AI to extract transformative insights from medical literature, thereby advancing functional medicine and preventative care [1][4] - Fifty1 AI Labs intends to fully acquire BioSpark, which will enhance its capabilities in identifying promising drug repurposing candidates [3][4] Group 2: Technological Integration - BioSpark's proprietary AI platform automates the extraction and structuring of clinical data, which will significantly improve the efficiency of identifying therapeutic patterns [2][3] - The integration of BioSpark's capabilities with Fifty1 AI Labs' Bayesian inference and polypharmacy modeling will create a new approach to drug repurposing based on real-world clinical data [3][4] Group 3: Strategic Vision - The alliance aims to dominate preventative healthcare through personalized, data-driven strategies and rapid identification of drug candidates [4][5] - Both companies share a commitment to enhancing human expertise with ethical AI tools, focusing on opportunities in functional medicine that traditional trials may overlook [5][6] Group 4: Company Background - BioSpark AI Technologies Inc. specializes in organizing real-world clinical data using proprietary AI and LLM technologies and holds a U.S. patent for its automation system [6] - Fifty1 AI Labs, a subsidiary of Fifty 1 Labs, Inc., focuses on AI-driven functional medicine, addressing critical needs in performance health and chronic disease prevention [7][8]

Core Insights - Fifty1 AI Labs, LLC has successfully completed the REVIVE Adaptive Platform Trial, the largest Long COVID study to date, addressing a health crisis affecting approximately 400 million people globally and 15% of COVID-19 survivors, with an economic burden exceeding USD 1 trillion annually [1][2] - The trial demonstrates a clear treatment benefit for Long COVID, aligning with Fifty 1 Labs, Inc.'s vision to revolutionize healthcare through AI-driven drug repurposing and functional medicine, targeting the $5.68 trillion biotech market [2][3] - The company aims to achieve a $50 million valuation and lead the $320.6 billion functional medicine market, enhancing investor confidence and positioning for uplisting to OTCQB by Q1 2026 and NASDAQ in the coming years [2][7] Company Achievements - The REVIVE Trial enrolled over 600 participants, achieving the fastest recruitment for a study of its kind, showcasing operational excellence and strategic partnerships with leading institutions [3][4] - Fifty1 AI Labs' proprietary AI platform, supported by a $1 million R&D investment, optimizes drug candidate selection and accelerates clinical research efficiency, setting a new standard in the industry [4][5] - The findings from the REVIVE Trial are expected to establish a foundation for polypharmacy-based treatment regimens, unlocking significant opportunities for intellectual property development and potential annual revenue in the billions [5][6] Strategic Initiatives - The company is pursuing regulatory pathways to bring novel therapies to market and establishing R&D hubs in Vancouver, alongside strategic partnerships with pharmaceutical leaders [7] - Upcoming initiatives include the launch of a minimum viable product website by July 24, 2025, and a fully interactive website by July 31, 2025, aimed at enhancing investor engagement [7] - A virtual shareholder teleconference is scheduled for July 28, 2025, to provide insights into the company's transformative vision and progress toward uplisting [7]

Core Insights - Fifty 1 Labs, Inc. (FITY) aims to achieve a $50 million valuation and lead the $320.6 billion functional medicine market, with a projected CAGR of 10.9% [1] - The company plans to uplist to the OTCQB by Q1 2026 and eventually to the NASDAQ Capital Market, demonstrating a commitment to growth and shareholder value [1][3] Group 1: Company Strategy - FITY's Game Plan focuses on AI-driven drug repurposing and functional medicine, targeting high-growth areas within the $5.68 trillion biotech market, which has a CAGR of 13.8% [2] - The company is investing a minimum of $1,000,000 in R&D through its subsidiary, Fifty1 AI Labs LLC, to develop an AI platform that integrates various data sources for drug repurposing [2][6] - Strategic acquisitions are planned, including targeting a biotech startup valued between $5 million and $10 million to enhance R&D capabilities [3] Group 2: Leadership and Commitment - The leadership team combines expertise in science, operations, and strategic planning, with key figures including CEO Paul Arora and Nobel laureate James Orbinski [4][5] - Officers and directors are deferring their salaries for two years until the $50 million valuation is achieved, alongside a personal investment of $350,000 to support R&D and expansion [6] - The company is committed to transparency with shareholders, planning a virtual conference in Q3 2025 and regular updates on progress [3] Group 3: Market Position and Innovation - FITY is leveraging AI to deliver personalized solutions for chronic diseases, positioning itself within the $320.6 billion functional medicine market [7] - The company plans to establish R&D hubs in Vancouver to enhance its market presence and operational capabilities [7] - The personalized medicine sector is projected to reach $900 billion by 2030, indicating significant growth potential for FITY [5]

Core Insights - Cosmos Health Inc. has announced its entry into the U.S. market and the launch of U.S.-based manufacturing through a strategic agreement with DolCas Biotech LLC [1][2] - The production will take place in GMP-certified facilities, enhancing operational control and reducing tariff exposure [2][4] - This partnership aims to strengthen Cosmos Health's position in the premium nutraceuticals market and expand its portfolio with scientifically backed ingredients [3][4] Company Overview - Cosmos Health Inc. is a diversified, vertically integrated global healthcare group, owning proprietary pharmaceutical and nutraceutical brands and operating a telehealth platform [6] - The company has established R&D partnerships targeting major health disorders and focuses on innovative product development [6] - Cosmos Health has a global distribution platform and is expanding throughout Europe, Asia, and North America [6] Partnership Details - The agreement with DolCas Biotech is expected to leverage DolCas's expertise in clinically validated formulations and vertically integrated manufacturing [3][4] - DolCas Biotech is recognized for its commitment to quality and innovation, with a portfolio that includes clinically supported nutraceutical products [5] - The partnership is seen as a strategic move to support Cosmos Health's growth in the U.S. and globally [4]

Core Viewpoint - Cosmos Health Inc. reported a strong financial performance for Q1 2025, showcasing a significant turnaround with improved profitability metrics and disciplined cost management. Financial Highlights - Revenue for Q1 2025 was $13.71 million, a decrease of 5.98% from $14.58 million in Q1 2024, attributed to a strategic shift towards higher-margin areas [6] - Gross profit increased by 53.70% to $2.05 million from $1.33 million in the prior-year period, driven by an improved product mix [6] - Adjusted EBITDA rose by 157.8% to $0.37 million compared to a loss of $0.64 million in Q1 2024 [6] - Adjusted Net Income improved by 139.4% to $0.28 million, versus a loss of $0.71 million in the prior-year period [6] Profitability and Cost Management - The company achieved profitability on an adjusted basis for both EBITDA and Net Income, reflecting improved gross profitability and effective cost management [3][9] - Total operating expenses declined by 9.05% to $2.88 million, with significant reductions in salaries and wages (17.34%) and sales and marketing expenses (83.78%) [6] Balance Sheet and Cash Flow - Stockholders' equity increased by $1.42 million, with a liabilities-to-assets ratio of 54.6%, indicating financial discipline [5] - Total assets rose by 5.3% to $57.2 million, while total liabilities increased by 4.9% to $31.24 million [7] - Operating cash burn improved by 94.5% year-over-year, decreasing to negative $0.19 million from negative $3.41 million in Q1 2024 [8] Operational Developments - The wholesale logistics segment (CosmoFarm) and the nutraceutical and pharmaceutical products portfolio, including Sky Premium Life®, were key contributors to the strong performance [4] - The company is advancing its R&D pipeline, with projects like the CCX0722 weight management solution nearing launch [11] - Cosmos Health is expanding its high-margin contract manufacturing segment and growing its flagship nutraceutical brand, Sky Premium Life, in global markets [11]

CHICAGO, May 15, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Highlights Income Statement Cosmos Health delivered ...

Core Insights - Cosmos Health Inc. has received an additional purchase order for 80,000 units of its Sky Premium Life products from Pharmalink in the UAE, following a successful sell-out of an initial order of 130,000 units [1][2] - The company aims to exceed 3 million units in cumulative orders over the first five years, supported by its exclusive distribution agreement with Pharmalink [2] - CEO Greg Siok highlighted the strong momentum of Sky Premium Life nutraceuticals in the UAE, emphasizing the effectiveness of the partnership with Pharmalink [3] Company Overview - Cosmos Health Inc. is a diversified, vertically integrated global healthcare group, incorporated in 2009 in Nevada, owning proprietary pharmaceutical and nutraceutical brands [3] - The company manufactures and distributes healthcare products, including pharmaceuticals, food supplements, and medical devices, through its subsidiary Cana Laboratories S.A., which is licensed under European Good Manufacturing Practices [3] - Cosmos Health is expanding its global distribution platform throughout Europe, Asia, and North America, with established offices and distribution centers in Greece and the UK [3]

Core Points - Cosmos Health Inc. has received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement of $1.00 per share, now due by November 3, 2025 [1][3] - The company was initially notified on November 6, 2024, that it was not in compliance as its stock price had been below $1.00 for 30 consecutive business days [2] - Cosmos Health continues to meet all other Nasdaq listing requirements and intends to regain compliance within the new timeframe [3] Company Overview - Cosmos Health Inc. is a diversified, vertically integrated global healthcare group, incorporated in 2009 in Nevada [4] - The company owns proprietary pharmaceutical and nutraceutical brands and operates a telehealth platform through its acquisition of ZipDoctor, Inc. [4] - It manufactures and distributes healthcare products, including pharmaceuticals and food supplements, and has established R&D partnerships targeting major health disorders [4]

Core Viewpoint - Cosmos Health Inc. has announced that its CEO, Greg Siokas, has significantly increased his ownership stake in the company by acquiring 1,466,764 common shares valued at $526,000, reflecting his confidence in the company's future prospects [1][2][3] Company Overview - Cosmos Health Inc. is a diversified, vertically integrated global healthcare group, incorporated in 2009 in Nevada, focusing on innovative R&D and owning proprietary pharmaceutical and nutraceutical brands [5] - The company manufactures and distributes healthcare products and operates a telehealth platform, with a global distribution network expanding throughout Europe, Asia, and North America [5] Recent Transactions - Greg Siokas has invested over $1.3 million in the past five months, increasing his total ownership to 5,582,066 common shares, with a cumulative investment exceeding $18 million since the company's inception [2][3] Product and Service Offerings - Cosmos Health owns a portfolio of brands including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept®, and C-Scrub®, and manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices under European Good Manufacturing Practices [5] - The company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, utilizing artificial intelligence for drug repurposing and focusing on novel patented nutraceuticals and innovative OTC products [5]

Core Insights - Cosmos Health Inc. reported a revenue increase of 2.0% to $54.43 million for FY 2024, driven by organic growth and contributions from prior acquisitions [5][12] - The company experienced a significant reduction in total operating expenses by 24.16% to $19.86 million, primarily due to cuts in general and administrative expenses and sales and marketing expenses [5][12] - Adjusted EBITDA was negative $3.73 million, a decline from positive $0.06 million in FY 2023, while adjusted net loss widened to $4.74 million from $0.81 million [5][12] Financial Performance - Revenue for FY 2024 was $54.43 million, up from $53.38 million in FY 2023 [5][12] - Gross margin decreased to 7.92% from 8.15% in FY 2023, attributed to a higher revenue mix from lower-margin logistics distribution [5] - Total operating expenses fell to $19.86 million from $26.18 million, with a 40.26% reduction in general and administrative expenses and a 71% decrease in sales and marketing expenses [5][12] Balance Sheet Overview - The liabilities-to-assets ratio was 55% at year-end 2024, indicating a balanced capital structure [3] - Total assets decreased by 17.72% to $54.31 million from $66.01 million at the end of 2023 [5][21] - Total liabilities slightly decreased by 0.64% to $29.78 million as of December 31, 2024 [5][21] R&D and Product Innovation - The company is leveraging AI-driven drug repurposing technologies and is advancing the commercialization of a proprietary weight loss drug [8] - Significant progress was made in securing long-term manufacturing agreements, enhancing revenue visibility [9] - The oncology portfolio was strengthened with the acquisition of two WIPO-patented anticancer drugs valued at over $24.5 million [11] Strategic Developments - The company expanded its nutraceutical brand, Sky Premium Life, with 60 new SKUs and launched the brand in Albania and Qatar [11] - A €2.2 million loan was secured against the CosmoFarm logistics center, providing strategic financial flexibility [10] - CEO Greg Siokas increased personal ownership by over 1 million shares, reflecting confidence in the company's long-term strategy [11]